Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400UEY9
Pharmaceuticals
OTC Markets Traded
| Market Cap | 91.23B 105B 84.1B 78.68B 147B 10,042B 150B 999B 388B 4,863B 396B 387B 16,912B | P/E Ratio 2026 * |
11.3x | P/E Ratio 2027 * | 10.6x |
|---|---|---|---|---|---|
| Enterprise Value | 103B 119B 95.2B 89.06B 166B 11,366B 170B 1,131B 439B 5,505B 448B 438B 19,143B | EV / Sales 2026 * |
2.19x | EV / Sales 2027 * | 2.03x |
| Free-Float |
89% | Yield 2026 * |
5.6% | Yield 2027 * | 5.93% |
Last Transcript: Sanofi
| 3 years | 75 |  | 106.5 |
| 5 years | 75 | | 106.5 |
| 10 years | 75 | | 106.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 105B | |
| +1.51% | +2.11% | +42.10% | +158.02% | 1,013B | |
| +1.08% | +5.59% | +55.18% | +50.67% | 574B | |
| -0.02% | -0.22% | +17.21% | +62.97% | 397B | |
| -0.46% | +4.97% | +21.24% | +15.95% | 324B | |
| +0.79% | +0.47% | +24.87% | +15.11% | 280B | |
| +2.08% | +5.28% | +25.73% | +34.26% | 273B | |
| +2.95% | +0.54% | +19.08% | +59.86% | 182B | |
| -0.55% | -0.81% | -45.51% | -48.53% | 194B | |
| +3.01% | -3.13% | +14.49% | +60.72% | 151B | |
| Average | +1.04% | +2.65% | +19.38% | +45.45% | 376.52B | |
| Weighted average by Cap. | +1.04% | +3.99% | +29.18% | +71.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.04B 54.36B 43.37B 40.57B 75.71B 5,178B 77.41B 515B 200B 2,508B 204B 200B 8,721B | 49.94B 57.7B 46.04B 43.07B 80.37B 5,497B 82.18B 547B 212B 2,662B 217B 212B 9,258B |
| Net income | 8.13B 9.4B 7.5B 7.02B 13.09B 895B 13.38B 89.09B 34.55B 434B 35.28B 34.52B 1,508B | 8.94B 10.32B 8.24B 7.71B 14.38B 984B 14.7B 97.86B 37.95B 476B 38.75B 37.92B 1,656B |
| Net Debt | 12.03B 13.9B 11.09B 10.38B 19.36B 1,324B 19.8B 132B 51.11B 641B 52.19B 51.07B 2,231B | 9.97B 11.52B 9.19B 8.6B 16.04B 1,097B 16.4B 109B 42.34B 531B 43.23B 42.3B 1,848B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
